This site is intended for
US Health Care Professionals only.

This site is intended for US Health Care Professionals only.

Empowering the Immune System to Fight Cancer

Immuno-Oncology research seeks to restore the body’s natural ability to fight cancer

NK cell mechanisms
Activating Inhibitory
SLAMF7 KIR
Effector T-cell mechanisms
Activating Inhibitory
CD137* CTLA-4
GITR* PD-1
OX40* LAG-3
  TIGIT*
Non-Effector
cell mechanisms
Inhibitory
CD73 CTLA-4
CSF1R IDO

*Pathways are listed by primary mechanisms. Secondary mechanisms may exist.

The immune system uses a network of signaling pathways to detect and eliminate tumor cells.1,2 Tumors use various mechanisms to escape detection and enable growth within the complex network.3,4

Ongoing Immuno-Oncology research at Bristol-Myers Squibb focuses on these pathways, either alone or in combination, to understand how they can be modulated to restore the body’s natural ability to fight cancer.


Research to further understand these pathways is ongoing.

Take a Closer Look at the Different Signaling Pathways

References

1. Leung J, Suh WK. The CD28-B7 Family in Anti-Tumor Immunity: Emerging Concepts in Cancer Immunotherapy. Immune Netw. 2014;14(6):265-276. 2. Long EO, Kim HK, Liu D, Peterson ME, Rajagopalan S. Controlling Natural Killer Cell Responses: Integration of Signals for Activation and Inhibition. Ann Rev Immunol. 2013;31:227-258. 3. Melero I, Berman DM, Aznar MA, Korman AJ, Gracia JLP, Haanen J. Evolving synergistic combinations of targeted immunotherapies to combat cancer. Nat Rev Cancer. 2014;15(8):457-472. 4. Smyth MJ, Ngiow SF, Ribas A, Teng MWL. Combination cancer immunotherapies tailored to the tumour microenvironment. Nat Rev Clin Oncol. 2016;13(3):143-158.